Stryker Corporation is a medical devices business based in the US. Stryker Corporation shares (SYK) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $355.60 – an increase of 3.03% over the previous week. Stryker Corporation employs 52,000 staff and has a trailing 12-month revenue of around $21.4 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $355.60 |
|---|---|
| 52-week range | $252.80 - $373.80 |
| 50-day moving average | $351.27 |
| 200-day moving average | $340.13 |
| Wall St. target price | $378.69 |
| PE ratio | 39.6875 |
| Dividend yield | $3.15 (0.9%) |
| Earnings per share (TTM) | $8.96 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $355.6 from 2024-10-11
| 1 week (2024-10-07) | 3.03% |
|---|---|
| 1 month (2024-09-13) | -3.96% |
| 3 months (2024-07-12) | 4.78% |
| 6 months (2024-04-12) | 3.96% |
| 1 year (2023-10-13) | 37.89% |
|---|---|
| 2 years (2022-10-14) | 70.04% |
| 3 years (2021-10-12) | 37.73% |
| 5 years (2019-10-14) | 71.01% |
Valuing Stryker Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Stryker Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Stryker Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 40x. In other words, Stryker Corporation shares trade at around 40x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Stryker Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.6119. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Stryker Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Stryker Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $5.5 billion.
The EBITDA is a measure of a Stryker Corporation's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $21.4 billion |
|---|---|
| Operating margin TTM | 21.19% |
| Gross profit TTM | $11.6 billion |
| Return on assets TTM | 7.24% |
| Return on equity TTM | 18.58% |
| Profit margin | 16.12% |
| Book value | $51.86 |
| Market Capitalization | $135.5 billion |
TTM: trailing 12 months
Dividend payout ratio: 28.5% of net profits
Recently Stryker Corporation has paid out, on average, around 28.5% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.9% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Stryker Corporation shareholders could enjoy a 0.9% return on their shares, in the form of dividend payments. In Stryker Corporation's case, that would currently equate to about $3.15 per share.
While Stryker Corporation's payout ratio might seem fairly standard, it's worth remembering that Stryker Corporation may be investing much of the rest of its net profits in future growth.
Stryker Corporation's most recent dividend payout was on 30 October 2024. The latest dividend was paid out to all shareholders who bought their shares by 29 September 2024 (the "ex-dividend date").
Stryker Corporation's shares were split on a 2:1 basis on 16 May 2004. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Stryker Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Stryker Corporation shares which in turn could have impacted Stryker Corporation's share price.
Over the last 12 months, Stryker Corporation's shares have ranged in value from as little as $252.7968 up to $373.7981. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Stryker Corporation's is 0.918. This would suggest that Stryker Corporation's shares are less volatile than average (for this exchange).
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.
Read our beginner’s guide to trading options in the US.